Clinical Trial Update: Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cetuximab as monotherapy in EGFR-negative metastatic colorectal cancer refractory to chemotherapy; results were posted after completion…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Colorectal Neoplasms, Metastases | Phase 2 | Status: COMPLETED | Results posted: 2009-10-23